Milrinone therapy in catecholamine-dependent critically ill patients with heart failure

Acta Anaesthesiologica Scandinavica

Volumn 44, Issue 4, 2000, Pages 403-409

  Siostrzonek, Peter ^a   Koreny, M ^b   Delle Karth, G ^b   Haumer, M ^b   Koller Strametz, J ^b   Heinz, G ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Catecholamine dependency; Heart failure; Milrinone

Indexed keywords

CATECHOLAMINE; DOBUTAMINE; MILRINONE; NORADRENALIN; PHOSPHODIESTERASE INHIBITOR; VASOCONSTRICTOR AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUID INTAKE; HEART FAILURE; HEMODYNAMICS; HUMAN; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; CARDIOTONIC AGENTS; CATECHOLAMINES; CRITICAL ILLNESS; DOBUTAMINE; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; MILRINONE; NOREPINEPHRINE; PHOSPHODIESTERASE INHIBITORS; PROSPECTIVE STUDIES;

EID: 0034015253     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-6576.2000.440408.x     Document Type: Article

References (24)

1. 1. Richard C, Ricome JL, Rimailho A, Botlineau G, Auzepy P. Combined hemodynamic effects of dopamine and dobutamine in cardiogenic shock. Circulation 1983: 67: 620-626.
2. 2. Monrad ES, Baim DS, Smith HS, Lanoue AS. Milrinone, dobutamine and nitroprusside: Comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation 1986: 73 (Suppl II): 168-174.
3. 3. Bristow MR, Ginsburg R, Minobe W, Cubicotti RS, Sagemann WS, Lurie K et al. Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. N Engl J Med 1982: 307: 205-211.
4. 4. Colucci WS, Denniss AR, Leatherman GF, Quigg RJ, Ludmer PL, Marsh JD et al. Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. J Clin Invest 1988: 81: 1103-1110.
5. 5. Remme WJ. Inodilator therapy for heart failure. Circulation 1993: 87 (Suppl IV): 97-107.
6. 6. Evans DB. Overview of vardiovascular physiologic and pharmacologic aspects of selective phosphodiesterase peak III inhibitors. Am J Cardiol 1989: 63: 9A-11A.
7. 7. Meissner A, Schmelzle T, Simon R. Differentialdiagnose des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin. Z Kardiol 1996: 85: 839-846.
8. 8. Vincent JL, Moreno R, Takala J, Willats S. The SOFA score to describe organ dysfunction/failure. Intensive Care Med 1996: 22: 707-710.
9. 9. Colucci WS. Observations on the intracoronary administration of milrinone and dobutamine to patients with congestive heart failure. Am J Cardiol 1989: 63: 17A-22A.
10. 10. Ludmer PL, Wright RF, Arnold MO, Ganz P, Braunwald E, Colucci WS. Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique. Circulation 1986: 73: 130-137.
11. 11. Monrad ES, McKay RG, Baim DS, Colucci WS, Fifer MA, Heller GV et al. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. Circulation 1984: 70: 1030-1037.
12. 12. Mager G, Klocke RK, Volkmann A, Kux A, Höpp HW, Hilger HH. Hämodynamik unter Dobutamin und Milrinon bei Patienten mit schwerer Herzinsuffizienz im intraindividuellen Vergleich. Z Kardiol 1991: 80: 149-157.
13. 13. Biddle TL, Benotti JR, Creager MA, Faxon DP, Firth BG, Fitzpatrick PG et al. Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. Am J Cardiol 1987: 59: 1345-1350.
14. 14. Baim DS. Effect of phosphodiesterase inhibition on myocardial oxygen consumption and coronary blood flow. Am J Cardiol 1989: 63: 23A-25A.
15. 15. Meissner A, Herrmann G, Gerdesmeyer L, Simon R. Additive Effekte von Milrinone und Dobutamin bei schwerer Herzinsuffizienz. Z Kardiol 1992: 81: 266-271.
16. 16. Höpp HW, Mager G, Klocke RK, Hilger HH. Aktivität des sympathischen und des Renin-Angiotensin-Aldosteronsystems bei schwerer Herzinsuffizienz in Abhängigkeit von Hämodynamik und Therapie. Intensivmed 1991: 28 (Suppl 1): 41-48.
17. 17. Muir AL, Nolan J. Modulation of venous tone in heart failure. Am Heart J 1991: 121: 1948-1950.
18. 18. Feneck RO. Intravenous milrinone following cardiac surgery: II. Influence of baseline hemodynamics and patient factors on therapeutic response. The European Milrinone Multicentre Trial Group. J Cardiothorac Vasc Anesth 1992: 6: 563-567.
19. 19. Vincent JL, Leon M, Berre J. The role of enoximone in the treatment of cardiogenic shock. Cardiology 1990: 77 (Suppl 3): 21-26.
20. 20. Naccarelli G, Goldstein RA. Electrophysiology of phosphodiesterase inhibitors. Am J Cardiol 1989: 63: 35A-40A.
21. 21. Ferrick KJ, Fein SA, Ferrick AM, Doyle JT. Effect of milrinone on ventricular arrythmias in congestive heart failure. Am J Cardiol 1990: 66: 431-434.
22. 22. Anderson JL, Baim DS, Fein SA. Efficiacy and safety of sustained intravenous infusions of milrinone in patients with severe congestive heart failure. J Am Coll Cardiol 1987: 9: 711-722.
23. 23. Bailey JM, Levy JH, Kikura M, Szlam F, Hug CC. Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery. Anesthesiology 1994: 81: 616-622.
24. 24. DeHert SG, Moens MM, Jorens PG, Delrue G, DePaep RJ, Vermeyen KM. Comparison of two loading doses of milrinone for weaning from cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1995: 9: 264-271.